Aim: To characterize the profile of patients seeking baclofen treatment for alcohol dependence in France. Method: We compared retrospectively baclofen seekers and baclofen non-seekers within a cohort of consecutive outpatients with alcohol dependence who attended a first appointment for alcohol treatment at two French addiction centres between September 2012 and March 2014. We documented socio-demographic characteristics; comorbid psychiatric, addiction, alcohol dependence features; patients' initial drinking goal, and referral status; and treatment retention at 6 and 12 months. Results: Of the 289 patients identified, 107 were baclofen seekers and 182 were baclofen non-seekers. The only parameters significantly associated with baclofen seekers in multivariate analyses were a greater baseline alcohol consumption (β = 15.4, 95% CI: 0.18-30.65, P = 0.05), a controlled-drinking initial goal (OR = 14.9, 95% CI: 7.7-29, P < 0.0001) and self-referral (OR = 6.6, 95% CI: 3.7-12, P < 0.0001), baclofen seekers being eight times more likely to be self-referred and treatment-naïve (OR = 8.8, 95% CI: 4.1-18.9, P < 0.0001). Baclofen seekers were more likely to be retained in treatment at 6 months (OR = 3.5, 95% CI: 1.8-6.7, P < 0.0001) and 12 months (OR = 1.9, 95% CI: 1.1-3.2, P = 0.019). Conclusion: In France, the perspective of controlled drinking offered by baclofen treatment may have attracted more self-referred patients, including those without previous alcohol treatment, to attend treatment, than the usual treatment options. These findings raise the question as to whether future public health strategies on alcohol should more prominently promote some aspects of alcohol treatment, such as patient's preference and treatment options, in order to reduce the treatment gap in alcohol dependence.
INTRODUCTION
Baclofen is a gamma amino-butyric acid type B receptor agonist that has been approved for spasticity in the 1970s (Sachais et al., 1977) . Since the late 2000s, a growing off-label use of baclofen for alcohol dependence has spread in France (Rolland et al., 2012) . This prescribing practice can reach very high doses, i.e. 300 mg/day or more (Dupouy et al., 2014; Rolland et al., 2014) . It has been introduced in France partly based on the personal experience of a physician who suffered from alcohol dependence and maintained that high dose baclofen could suppress his dependence (Ameisen 2005 (Ameisen , 2008 . His story was emphasized in the media, and active lobbying physician-patient associations emerged and promoted the use of baclofen as a possible way to resume control over drinking (Rolland et al., 2012) . This had led to numerous demands for baclofen by patients, either to their general practitioner or to addiction teams.
In March 2014, the French National Safety Agency for Medicines and Health Products (Agence Nationale de Sécurité des Médicaments et des produits de santé; ANSM) issued a temporary recommendation for use (TRU) (ANSM, 2014) , pending the results of two efficacy French trials on high dose baclofen. The use of baclofen according to the TRU measure has now been officially recommended by the French Alcohol Society (Rolland et al., 2016) . However, before the TRU, the framing of the baclofen prescribing was mainly based on local initiatives (ANSM, 2013) . For example, several years before the TRU, the University Hospital of Lille (CHU Lille) had developed a regional team-based off-label system named CAMTEA ('Consultations d'Avis Multidisciplinaire pour les Traitements d'Exception en Addictologie'-Team-based consultations for off-label medications in Addiction Medicine) which offered team-based protocolled baclofen prescriptions. CAMTEA allowed the regional addiction teams to meet the growing demands for baclofen in a highly supervised framework with pharmacovigilance support (Rolland et al., 2010) . In the CAM-TEA system, baclofen treatment was prescribed only on patients' express demand. In contrast, no baclofen prescription was performed outside CAMTEA in the centres belonging to this regional system. Using a cohort of patients which consisted of the pooled active lists of patients of two regional outpatient addiction centres, we compared the profile of baclofen seekers (i.e. the patients included in the CAMTEA system for baclofen prescriptions) vs. the profile of baclofen non-seekers (i.e. the patients followed in the usual outpatient consultations). We notably compared, between the two groups, sociodemographic characteristics, comorbid psychiatric and addictive characteristics, and alcohol dependence features, as well as the patients' initial drinking goal and referral status and treatment retention during the 12 months following the initial appointment. The objective of the study was to identify specific characteristics in the profile of baclofen seekers in France.
MATERIALS AND METHODS

Subjects and centres
A cohort of subjects was constituted using the comprehensive active list of two outpatient addiction centres (i.e. Lille and Béthune, North of France). We only included patients: (a) who were diagnosed with alcohol dependence (ICD-10 criteria), based on the electronic medical system of each centre; and (b) attended at least one appointment in one of the two centres between September 2012 and March 2014. Of the 396 (Béthune: 262, Lille: 134) consecutive patients who attended a first appointment for alcohol treatment between September 2012 and March 2014, we identified 289 patients (Béthune: 172; Lille: 117) with an ICD-10 diagnosis of alcohol dependence; 107 subjects with hazardous or harmful drinking were not included (none of them received baclofen treatment). We then separated the 289 subjects with alcohol dependence into two groups: (a) the baclofen seekers and (b) the baclofen non-seekers. Of note, four patients who were initially seeking baclofen treatment but in whom baclofen treatment was never introduced because of contra-indications were considered as baclofen seekers. Conversely, eleven patients who were not initially seeking baclofen treatment received baclofen treatment during the follow-up period; but as baclofen treatment was not their initial demand, those patients were considered as baclofen non-seekers.
At the Lille centre, all patients were offered 30-minute sessions of medical management every two weeks during the first three months of treatment and then one session every month; supportive therapy by nurses and/or structured psychotherapies by psychologists were available on patients' demand. At the Béthune centre, all patients were offered 1-hour sessions of supportive therapy by nurses every two weeks and a 30-minute session of medical consultations once a month during the first three months of treatment and then every two months; structured psychotherapies by psychologists were available on patients' demand. At the two centres, the pharmacotherapeutic options for baclofen non-seekers were based on acamprosate, naltrexone or disulfiram. The centres' effect has been adjusted for in the multivariate analyses.
Baclofen: initiation, dosage and procedures of dosage's increment As previously mentioned, baclofen was initiated on patients' demand only, but patients had to have tried unsuccessfully or refused the firstline medications recommended for abstinence maintenance in France, i.e. acamprosate and naltrexone (but not disulfiram, which is not a first-line option in France) (Rolland et al., 2016) . Most of the time, baclofen was started at the first consultation when there were no clinical and biological contra-indications when such information was immediately available. However, sometimes the start of the treatment could have occurred at the second consultation after having obtained such information. Baclofen was initiated at a 30 mg/day dosage and increased by 15 mg/day every three days. The reason for this titration is because baclofen induced adverse events, especially sedation, are known to be dose-related (Rolland et al., 2015) . The maximum prescribed dosage of baclofen depended on individual criteria for both efficacy and tolerability. The maximum baclofen dosage in our system was 300 mg/day.
Data recorded
The following data were extracted from the medical records of patients of both groups: (a) current ICD-10 criteria tobacco dependence (yes/no), (b) current ICD-10 criteria for comorbid substance use disorder (yes/no), (c) living alone (yes/no), (d) occupational status (employed, unemployed, retired), (e) psychiatric history (ICD-10 diagnoses) other than substance use disorder (yes/no), (f) alcohol-related medical complications (yes/no), (g) past history of alcohol treatment (yes/no), (h) average weekly alcohol consumption (AWAC) in the month before the first appointment in grams per week (g/w) as assessed by the Alcohol Timeline Follow-Back 30 days (Sobell and Sobell, 1992) , (i) patient's drinking goal at baseline (abstinence vs. controlled drinking), ( j) patient's referral status (i: selfreferred; ii: not self-referred), (k) retention in treatment at 6 months (yes/no), and (l) retention in treatment at 12 months (yes/no). Data on baclofen maximum dosage (mg/day), baclofen discontinuation status (yes/no) and presence of a favourable drinking outcome (yes/no) were also collected at 6 and 12 months. The ICD-10 diagnoses (WHO, 2007) were made by standard assessment through clinical interview. Treatment retention was considered independently of whether baclofen had been stopped during the follow-up period. Having a favourable drinking outcome was defined as consuming alcohol at a low-risk level for patients without liver cirrhosis and/or acute/chronic pancreatitis and abstinence for patients with liver cirrhosis and/or acute/chronic pancreatitis, as assessed by the Timeline Follow-Back 30 days.
Statistical analyses
Quantitative variables are expressed as mean (standard deviation) in case of normal distribution or as median (interquartile range) otherwise. Qualitative variables are expressed as numbers ( percentage). Normality of distributions was assessed using histograms and Shapiro-Wilk tests. Bivariate comparisons between baclofen seekers and baclofen non-seekers were performed using Student's t tests for quantitative variables (Mann-Whitney U tests was used for non-Gaussian distribution) and Chi-squared tests for categorical variables (Fisher's exact tests were used when expected values were less than 5 at the Chi-squared test). The relationship between the baclofen status and each clinical variable was investigated by using a multivariable logistic regression model. The analyses were adjusted for baseline characteristics. These baseline characteristics were selected both on the basis of the results of bivariate analysis (P-value <0.2) and on the basis of clinical expertise. We derived from the logistic regression model adjusted odds ratio (OR) with their 95% confidence interval (CI) as effect size measure. Statistical testing was performed at the two-tailed α level of 0.05. Data were analysed using SAS software (version 9.3, SAS Institute Inc., Cary, NC, USA).
Ethical aspects
We obtained the approval of two French committees to utilize the data mentioned in this manuscript (Avis CNIL #1851299; Avis CCTIRS #13.290).
RESULTS
Among the 289 consecutive patients with alcohol dependence who attended a first appointment for alcohol treatment in one of the two centres between 1 September 2012 and 1 March 2014, 107 were initially seeking a baclofen treatment.
Descriptive data and between-group bivariate analyses on sociodemographic characteristics, comorbid psychiatric and addictive characteristics and alcohol dependence features as well as on patient's initial drinking goal and referral status at baseline are detailed in Table 1 . Descriptive data and between-group bivariate analyses on treatment outcomes at 6 and 12 months are detailed in Table 2 . Results obtained using multivariate analyses are displayed in Table 3 .
In our sample, baclofen seekers were similar to usual treatment seekers in terms of socio-demographic characteristics, comorbid substance use disorder, alcohol-related medical history and past history of alcohol treatment. While no significant between-group difference was found in psychiatric disorders overall using bivariate analyses, Table 1 . Baseline characteristics and between-group comparisons using bivariate analyses
Baseline characteristics
Baclofen seekers n = 107 n (%)
Baclofen non-seekers n = 182 n (%) the rate of comorbid anxious disorders was however significantly higher in baclofen seekers (P = 0.047). Baclofen seekers were also significantly more likely to have a greater baseline AWAC (P = 0.03), to express a controlled-drinking initial goal (P < 0.0001) and to be self-referred (P < 0.0001). In addition, despite a high rate of baclofen discontinuation (55% at 12 months), treatment retention was significantly higher in baclofen seekers at 6 and 12 months. This difference was similar in patients with and without a history of alcohol treatment at 6 months, but remained significant at 12 months only in patients without history of alcohol treatment. Of note, no significant between-group difference was found in drinking outcomes. When using multivariate analyses, the only parameters significantly associated with baclofen seekers were a greater baseline alcohol consumption (β = 15.4, 95% CI: 0.18-30.65, P = 0.05), a controlleddrinking initial goal (OR = 14.9, 95% CI: 7.7-29, P < 0.0001) and selfreferral as referral status (OR = 6.6, 95% CI: 3.7-12, P < 0.0001); baclofen seekers being eight times more likely to be self-referred and treatment-naïve (OR = 8.8, 95% CI: 4.1-18.9, P < 0.0001). Baclofen seekers were also more likely to be retained in treatment at 6 months (OR = 3.5, 95% CI: 1.8-6.7, P < 0.0001) and 12 months (OR = 1.9, 95% CI: 1.1-3.2, P = 0.019).
DISCUSSION
The aim of our study was to compare the characteristics of baclofen seekers versus those of baclofen non-seekers, among all the patients with alcohol dependence who attended a first appointment for alcohol treatment at two different French outpatient addiction centres in order to identify specific characteristics associated with baclofen seekers in France.
Regarding baseline characteristics, the bivariate analyses found that baclofen seekers were similar to usual treatment seekers in terms of socio-demographic characteristics, comorbid substance use disorder, alcohol-related medical history and past history of alcohol treatment. Although there was no significant between-group difference in the rate of depressive disorders, the rate of comorbid anxious disorders was significantly higher in baclofen seekers and bivariate analyses revealed that baclofen seekers were more likely to display: (a) a greater When patients who were initially seeking baclofen treatment but in whom baclofen treatment was never introduced because of contra-indications were still in treatment, baclofen was considered as discontinued.
b Favourable drinking outcomes = consumption at a low-risk level for patients without liver cirrhosis and/or acute/chronic pancreatitis and abstinence for patients with liver cirrhosis and/or acute/chronic pancreatitis as assessed by the Alcohol Timeline Follow-Back 30 days (Sobell and Sobell, 1992) . baseline AWAC, (b) a controlled-drinking initial goal and (c) selfreferral as referral status, regardless the presence of a past history of alcohol treatment. Although comorbid anxious disorder was not significant in the multivariate model, the bivariate significant result should be appreciated in the light of a recent Australian study which suggested found that baclofen might be more beneficial for patients with comorbid anxious disorder (Morley et al., 2014) . The only parameters significantly associated with baclofen seekers in multivariate analyses (after adjustment for inter alia centres' effect) were a greater baseline AWAC, a controlled-drinking initial goal and self-referral, baclofen seekers being eight times more likely to be self-referred and treatment-naive.
Regarding treatment outcomes, bivariate analyses showed that treatment retention was significantly higher in baclofen seekers at both 6 and 12 months; but while this effect was similar in patients with and without history of alcohol treatment at 6 months, the between-group differences remain significant at 12 months only in patients without history of alcohol treatment. This trend was confirmed in multivariate analyses. Nevertheless, the findings on treatment retention should be interpreted with great caution. Because our study was not a double blind study, it is impossible to determine whether the differences observed in treatment retention are due to an initial baclofen-seeking effect or to the particular supervision offered to patients by the CAMTEA system. Anyway, those differences do not seem to be explained by between-group discrepancies in treatment effectiveness since no significant difference in favourable drinking outcomes at 6 and 12 months was found in bivariate analyses between the two groups. However, because the rate of baclofen discontinuation was higher at 12 months than at 6 months, the weakening of the between-group difference in treatment retention at 12 months among patients with a past history of alcohol treatment could be due to the disappointment of some patients in whom baclofen was not as efficacious as initially hoped. Nevertheless, those findings suggest that help seeking in baclofen seekers was not just transient, and was even persistent in some baclofen seekers after baclofen discontinuation.
Those findings are particularly interesting in regard of the known treatment gap in alcohol dependence. Indeed, it has been estimated that only around 35% of people with a current diagnosis of alcohol dependence in western countries have ever sought and received help (Oleski et al., 2010; Rehm et al., 2015) and less 25% are currently receiving help (Rehm et al., 2012 (Rehm et al., , 2015 . Our findings suggest that baclofen seeking in France might have attracted to care at least some people with alcohol dependence currently untreated, including some without previous alcohol treatment since we found that baclofen seekers were more likely to be self-referred and treatment-naive than usual treatment seekers and that baclofen seekers without a history of alcohol treatment were more likely be retained in treatment over time than usual treatment seekers without a history of alcohol treatment.
Explanations for these findings are surely numerous and complex. However, in the light of the existing literature and of our findings, some hypotheses can be raised. Indeed, a recent study on treatment utilization for AUDs in Europe (Rehm et al., 2015) , which included detailed sections on alcohol dependence, showed that alcohol consumption and anxiety were among the most predictive variables for treatment seeking in alcohol dependence. In regard of our findings, baclofen-seeking behaviour could have emphasized this phenomenon since baclofen seekers had a greater baseline AWAC and a higher rate of anxious disorders than usual treatment seekers. In addition, baclofen has been exhibited in the media as a means to control drinking in alcohol dependence (Rolland et al., 2012) . It should be mentioned that, at that time, nalmefene (licensed for reduction of drinking) had not been marketed in France, and no other medication for alcohol dependence had ever received such media attention. Given that the reluctance to engage in abstinence appears to be an important limiting factor for access to care in alcohol use disorder (Saunders et al., 2006; Luquiens and Aubin, 2014) and that patients' initial drinking goal does not seem mediated by alcohol dependence severity (Adamson et al., 2010) , baclofen seekers may have been attracted by this new type of strategy-in line with the recent development of treatment strategies based on better meeting the patients' preferences and in order to reach patients who are reluctant or resistant to an abstinencebased treatment (Luquiens and Aubin, 2014) . Finally the intensive media coverage of baclofen in the years during which the patients were treated (Rolland et al., 2012) should not be disregarded as the media craze on baclofen could have, at least partly, fostered treatmentseeking in untreated people with alcohol dependence. Indeed, given that shame is a commonly reported reason for not seeking treatment (Andréasson et al., 2013) , presenting oneself as seeking baclofen treatment (rather than usual help) could have been perceived as less stigmatizing for some untreated people with alcohol dependence. Nevertheless, this hypothesis would require further investigation.
Several limitations should be acknowledged. First, it was conducted in only two centres of the same region, and we cannot thus ascertain that the results were not impacted by local features. Second, we have already pointed out the retrospective and observational nature of our study, which dramatically limits the possibility of addressing the causal factors underlying our findings. However, the baseline analyses are not likely to have been affected by this limitation. Another limitation is that ICD-10 diagnoses were not documented with a structured interview instrument; but as all ICD-10 diagnoses were made through clinical interview by addiction specialists with at least three years of clinical experience, we believe that misdiagnoses were limited. Finally, it should be noticed that eleven patients who were not initially seeking baclofen treatment received baclofen treatment during the follow-up period (five of them were still in treatment at 6 and 12 months, but only two displayed favourable drinking outcomes at 12 months). Conversely, four patients who were initially seeking baclofen treatment but in whom baclofen treatment was never introduced because of contraindications were considered as baclofen seekers (two of them were still in treatment at 6 months and only one at 12 months; none of them displayed favourable drinking outcomes at 12 months). However those issues cannot have impacted our baseline analyses and their effect on treatment outcomes is surely limited given the small frequency of those phenomena (11/182, 6.0% and 4/107, 3.7% respectively).
In conclusion, we found that the availability of baclofen treatment in France may have attracted patients who were aiming for controlling drinking. Interestingly, this treatment option seems to have attracted a greater proportion of treatment-naïve self-referred patients, which raise the question as to whether future public health strategies on alcohol should more prominently promote some aspects of alcohol treatment, such as patient's preference and treatment options, in order to reduce the treatment gap.
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